Filter Results

Locations

Study status

(for at least one location)

Gender

Age

Healthy Volunteer

What is this?
A volunteer subject with no known significant health problems who participates in research to test a new drug, device or intervention. These volunteers are recruited to serve as controls for patient groups. Healthy volunteers receive the same test, procedure, or drug the patient group receives.

Study phase

What is this?
During the early phases (phases 1 and 2), researchers assess safety, side effects, optimal dosages and risks/benefits. In the later phase (phase 3), researchers study whether the treatment works better than the current standard therapy. They also compare the safety of the new treatment with that of current treatments. Phase 3 trials include large numbers of people to make sure that the result is valid. There are also less common very early (phase 0) and later (phase 4) phases. Phase 0 trials are small trials that help researchers decide if a new agent should be tested in a phase 1 trial. Phase 4 trials look at long-term safety and effectiveness, after a new treatment has been approved and is on the market.

Search Results 5001-5010 of 8984

  • Results filtered:
  • Locations: Rochester, MN
Edit search filters
  1. InSpace Accelerated Rehabilitation Study (IAccelerate)

    Rochester, MN

  2. A Study To Assess Adverse Events And Change In Disease Activity In Adult Participants Receiving Intravenously Infused Telisotuzumab Adizutecan Alone Or With Standard Of Care In Participants With Post Adjuvant Circulating Tumor DNA Positive Colorectal Cancer And No Radiographic Evidence Of Disease

    Jacksonville, FL, Rochester, MN

  3. Long-Term Study Of Participants Previously With Ciltacabtagene Autoleucel

    Scottsdale/Phoenix, AZ, Rochester, MN

  4. A Study Comparing CAR-T Therapy Versus Pomalidomide, Bortezomib And Dexamethasone (PVd) Or Daratumumab, Pomalidomide And Dexamethasone (DPd) In Participants With Relapsed And Lenalidomide-Refractory Multiple Myeloma

    Scottsdale/Phoenix, AZ, Rochester, MN

  5. Study Of Lenzilumab And Axicabtagene Ciloleucel In Subjects With Relapsed Or Refractory Large B-cell Lymphoma

    Rochester, MN

  6. Daratumumab Retreatment In Participants With Multiple Myeloma Who Have Been Previously Treated With Daratumumab Intravenous (Dara-IV)

    Rochester, MN

  7. Expanded Access Program With Nivolumab (BMS-936558) In Combination With Ipilimumab (Yervoy®) In Anti-CTLA-4 Treatment-Naïve Subjects With Unresectable Or Metastatic Melanoma (CheckMate 218)

    Scottsdale/Phoenix, AZ, Jacksonville, FL, Rochester, MN

  8. Nivolumab In Treating Patients With Relapsed Or Refractory Peripheral T-cell Lymphoma

    Scottsdale/Phoenix, AZ, Jacksonville, FL, Rochester, MN

  9. Ipilimumab And Nivolumab As Adjuvant Treatment Of Mucosal Melanoma

    Rochester, MN

  10. An Investigational Immuno-therapy Study To Assess The Safety, Tolerability And Effectiveness Of Anti-LAG-3 With And Without Anti-PD-1 In The Treatment Of Solid Tumors

    Rochester, MN

.

Mayo Clinic Footer